Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-48

Jumping on your answer to @thetooch others have pointed out already.
You need blood vessels to deliver anything that is administered via IV, as these tumours have "...dense fibrous tissue and lack of blood vessels supplying the tumours have been shown to limit therapy uptake..." then anything that can be done to maximize delivery to specifically those tissues is a huge bonus.

Given that this TAMP platform has been demonstrated to delivery of 100 times more than standard IV, it not only means you can get to these hard to reach tumours, but it could potentially allow more direct targeting and lower initial dosages of the drugs being delivered.
This improved delivery concentration would allow scope to increase dosages for follow up treatments if required.
In effect, you get more headroom for the treatment.

This is of course provided they can get the platform and CF33 to play nicely together. We'll know in 4 months. If it doesn't work, the dosage window of the CF33 suite is so very large, it's not a total train smash at all. This is a delivery optimisation in my opinion, but a valuable one if they get it to work.